MVA-SIBP not checked
Shanghai Institute Of Biological Products
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants received one subcutaneous dose of 0.5ml MVA-SIBP high dose on days 0 and 28, respectively, for a total of two doses.”In the company’s words, NCT07253675 on ClinicalTrials.gov
- Tested for
- Monkeypox (Mpox), Monkeypox
- Main trialPhase 2
- “To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).”In the company’s words, NCT07253675 on ClinicalTrials.gov
Other drugs for Monkeypox (Mpox)
Coming up1
- 28 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 28 Feb 2027 | Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo | |
| Phase 1Recruiting | 30 Jan 2026 | A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026